Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial.

Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR.

Haematologica. 2019 Apr 4. pii: haematol.2018.214429. doi: 10.3324/haematol.2018.214429. [Epub ahead of print]

2.

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.

Nahas MR, Stroopinsky D, Rosenblatt J, Cole L, Pyzer AR, Anastasiadou E, Sergeeva A, Ephraim A, Washington A, Orr S, McMasters M, Weinstock M, Jain S, Leaf RK, Ghiasuddin H, Rahimian M, Liegel J, Molldrem JJ, Slack F, Kufe D, Avigan D.

Br J Haematol. 2019 May;185(4):679-690. doi: 10.1111/bjh.15818. Epub 2019 Mar 3.

3.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1347-1354. doi: 10.1016/j.bbmt.2019.02.022. Epub 2019 Mar 1.

PMID:
30826465
4.

A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.

Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A, Mehrens J, He H, Alatrash G, Sukhumalchandra P, St John L, Clise-Dwyer K, Zha D, Molldrem JJ.

Front Immunol. 2019 Jan 18;9:3153. doi: 10.3389/fimmu.2018.03153. eCollection 2018.

5.

Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity.

Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM.

Nat Commun. 2019 Jan 16;10(1):254. doi: 10.1038/s41467-018-08109-6.

6.

Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.

Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA.

Clin Cancer Res. 2019 Apr 15;25(8):2610-2620. doi: 10.1158/1078-0432.CCR-18-1527. Epub 2019 Jan 15.

PMID:
30647079
7.

Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens.

Lansford JL, Dharmasiri U, Chai S, Hunsucker SA, Bortone DS, Keating JE, Schlup IM, Glish GL, Collins EJ, Alatrash G, Molldrem JJ, Armistead PM, Vincent BG.

Blood Adv. 2018 Aug 28;2(16):2052-2062. doi: 10.1182/bloodadvances.2018022475.

8.

Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Yang TH, St John LS, Garber HR, Kerros C, Ruisaard KE, Clise-Dwyer K, Alatrash G, Ma Q, Molldrem JJ.

J Immunol. 2018 Sep 1;201(5):1389-1399. doi: 10.4049/jimmunol.1800324. Epub 2018 Jul 18.

9.

Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.

Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ.

Clin Cancer Res. 2018 Jul 15;24(14):3386-3396. doi: 10.1158/1078-0432.CCR-17-2626. Epub 2018 Apr 16.

10.

Targeting PR1 in myeloid leukemia.

Alatrash G, Molldrem JJ, Qazilbash MH.

Oncotarget. 2017 Dec 18;9(4):4280-4281. doi: 10.18632/oncotarget.23403. eCollection 2018 Jan 12. No abstract available.

11.

Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.

Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G.

Front Immunol. 2018 Jan 25;8:1975. doi: 10.3389/fimmu.2017.01975. eCollection 2017.

12.

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA.

Cancer Res. 2017 Oct 1;77(19):5374-5383. doi: 10.1158/0008-5472.CAN-16-2774. Epub 2017 Aug 17.

13.

Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.

Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ.

J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.

14.

Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone.

Kolonin MG, Sergeeva A, Staquicini DI, Smith TL, Tarleton CA, Molldrem JJ, Sidman RL, Marchiò S, Pasqualini R, Arap W.

Cancer Res. 2017 Jun 15;77(12):3144-3150. doi: 10.1158/0008-5472.CAN-16-0708. Epub 2017 Apr 20.

15.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ.

Cancer Immunol Res. 2017 Apr;5(4):319-329. doi: 10.1158/2326-6066.CIR-16-0141. Epub 2017 Mar 2.

16.

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ.

Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.

17.

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.

Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM.

Leukemia. 2017 Jan;31(1):234-237. doi: 10.1038/leu.2016.249. Epub 2016 Aug 30. No abstract available.

18.

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.

Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK, Perez-Soler R.

PLoS One. 2016 Jul 28;11(7):e0160004. doi: 10.1371/journal.pone.0160004. eCollection 2016.

19.

PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.

St John LS, Wan L, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ, Bollard CM, Ma Q, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):995-1001. doi: 10.1016/j.jcyt.2016.05.007.

20.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.

21.

Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.

Chawla A, Alatrash G, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Diaconu I, Gall V, Neal S, Peters HL, Clise-Dwyer K, Molldrem JJ, Mittendorf EA.

Cancer Immunol Immunother. 2016 Jun;65(6):741-51. doi: 10.1007/s00262-016-1841-6. Epub 2016 Apr 29.

22.

Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.

Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You MJ, Gagea M, Ma Q, Molldrem JJ.

Leukemia. 2016 Jul;30(7):1475-84. doi: 10.1038/leu.2016.57. Epub 2016 Mar 8.

23.

Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.

Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ.

Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1555-64. doi: 10.1073/pnas.1521812113. Epub 2016 Feb 29.

24.

PAND: A Distribution to Identify Functional Linkage from Networks with Preferential Attachment Property.

Li H, Tong P, Gallegos J, Dimmer E, Cai G, Molldrem JJ, Liang S.

PLoS One. 2015 Jul 9;10(7):e0127968. doi: 10.1371/journal.pone.0127968. eCollection 2015.

25.

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.

Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ.

Blood. 2015 May 7;125(19):2885-92. doi: 10.1182/blood-2015-01-607366. Epub 2015 Mar 16.

26.

A GVHD kill switch helps immune reconstitution.

Molldrem JJ, Lu S.

Blood. 2014 Jun 19;123(25):3849-50. doi: 10.1182/blood-2014-05-572883.

27.

PD-L1 expression in triple-negative breast cancer.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G.

Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.

28.

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ.

Cytotherapy. 2014 Jan;16(1):90-100. doi: 10.1016/j.jcyt.2013.07.009. Epub 2013 Oct 26.

29.

CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis.

Dondossola E, Rangel R, Guzman-Rojas L, Barbu EM, Hosoya H, St John LS, Molldrem JJ, Corti A, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20717-22. doi: 10.1073/pnas.1321139110. Epub 2013 Dec 2.

30.

Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.

PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.

31.

Kernel machine SNP-set testing under multiple candidate kernels.

Wu MC, Maity A, Lee S, Simmons EM, Harmon QE, Lin X, Engel SM, Molldrem JJ, Armistead PM.

Genet Epidemiol. 2013 Apr;37(3):267-75. doi: 10.1002/gepi.21715. Epub 2013 Mar 7.

32.

Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.

Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG.

PLoS One. 2012;7(12):e51390. doi: 10.1371/journal.pone.0051390. Epub 2012 Dec 19.

33.

Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ.

N Engl J Med. 2012 Dec 13;367(24):2305-15. doi: 10.1056/NEJMoa1207285.

34.

A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G.

Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12.

35.

Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.

Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ.

J Immunol. 2012 Dec 1;189(11):5476-84. doi: 10.4049/jimmunol.1201221. Epub 2012 Oct 26.

36.

dsPIG: a tool to predict imprinted genes from the deep sequencing of whole transcriptomes.

Li H, Su X, Gallegos J, Lu Y, Ji Y, Molldrem JJ, Liang S.

BMC Bioinformatics. 2012 Oct 19;13:271. doi: 10.1186/1471-2105-13-271.

37.

What T cells see in WT-1.

Molldrem JJ.

Blood. 2012 Aug 23;120(8):1540-1. doi: 10.1182/blood-2012-06-433979.

38.

Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.

Ma Q, Li D, Nurieva R, Patenia R, Bassett R, Cao W, Alekseev AM, He H, Molldrem JJ, Kroll MH, Champlin RE, Sale GE, Afshar-Kharghan V.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1174-81. doi: 10.1016/j.bbmt.2012.05.014. Epub 2012 Jun 1.

39.

Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response.

Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ.

Cancer Res. 2012 Jul 1;72(13):3153-62. doi: 10.1158/0008-5472.CAN-11-4135. Epub 2012 May 7.

40.

Vitamin D receptor upregulation in alloreactive human T cells.

Joseph RW, Bayraktar UD, Kim TK, St John LS, Popat U, Khalili J, Molldrem JJ, Wieder ED, Komanduri KV.

Hum Immunol. 2012 Jul;73(7):693-8. doi: 10.1016/j.humimm.2012.04.019. Epub 2012 Apr 28.

PMID:
22548720
41.

The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ.

J Immunother. 2012 May;35(4):309-20. doi: 10.1097/CJI.0b013e31824b3b14.

42.

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG.

Clin Cancer Res. 2012 May 1;18(9):2465-77. doi: 10.1158/1078-0432.CCR-11-2034. Epub 2012 Feb 3.

43.

Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients.

Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18637-42. doi: 10.1073/pnas.1114503108. Epub 2011 Nov 2.

44.

Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.

Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M.

Blood. 2011 Nov 24;118(22):5957-64. doi: 10.1182/blood-2011-06-362111. Epub 2011 Oct 3.

45.

Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.

Armistead PM, Liang S, Li H, Lu S, Van Bergen CA, Alatrash G, St John L, Hunsucker SA, Sarantopoulos S, Falkenburg JH, Molldrem JJ.

PLoS One. 2011;6(8):e23217. doi: 10.1371/journal.pone.0023217. Epub 2011 Aug 9.

46.

Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.

Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW.

Clin Cancer Res. 2011 Sep 15;17(18):5945-52. doi: 10.1158/1078-0432.CCR-11-0970. Epub 2011 Aug 3.

47.

PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo.

Tao RH, Berkova Z, Wise JF, Rezaeian AH, Daniluk U, Ao X, Hawke DH, Karp JE, Lin HK, Molldrem JJ, Samaniego F.

Blood. 2011 Sep 15;118(11):3107-18. doi: 10.1182/blood-2011-04-349670. Epub 2011 Jul 29.

48.

Vaccines as consolidation therapy for myeloid leukemia.

Alatrash G, Molldrem JJ.

Expert Rev Hematol. 2011 Feb;4(1):37-50. doi: 10.1586/ehm.10.80. Review.

49.

An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ.

Blood. 2011 Apr 21;117(16):4262-72. doi: 10.1182/blood-2010-07-299248. Epub 2011 Feb 4.

50.

Preparing basic and translational grant proposals: thoughts from the trenches.

Molldrem JJ.

Hematology Am Soc Hematol Educ Program. 2010;2010:181-4. doi: 10.1182/asheducation-2010.1.181. Review.

PMID:
21239790

Supplemental Content

Loading ...
Support Center